CCE
0.35
75%
H2G
0.006
-33.3%
PGO
0.17
61.9%
M2R
0.002
-33.3%
IOV
0.535
57.4%
PEN
0.245
-32.9%
CLA
0.006
50%
MNB
0.017
-29.2%
SGA
0.089
48.3%
TRP
0.078
-29.1%
OFX
0.77
46.7%
CCA
0.052
-25.7%
SLB
0.215
43.3%
SLD
0.4
-25.2%
KEY
0.135
42.1%
CAN
0.003
-25%
NVU
0.061
41.9%
IRD
0.009
-25%
AMD
0.007
40%
MOH
0.006
-25%
ION
0.04
37.9%
JGH
0.076
-24%
EV1
0.011
37.5%
ALV
0.017
-22.7%
G50
0.66
37.5%
OLY
0.04
-21.6%
LDX
0.11
37.5%
AZ9
0.015
-21.1%
BNZ
3.26
35.8%
LRM
0.019
-20.8%
ECT
0.135
35%
HRE
0.032
-20%
MYE
0.45
32.4%
IPD
0.004
-20%
CG1
0.088
31.3%
RAP
0.024
-20%
CPN
0.13
30%
FTI
0.49
-18.3%
FMN
0.195
30%
BST
0.32
-17.9%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Control Bionics (ASX:CBL): Expands global reach with exclusive UK and Ireland distribution agreement

Control Bionics (ASX:CBL) expands global reach with exclusive UK and Ireland distribution agreement.

• Exclusive distribution of NeuroNode® by Smart Box in the UK and Ireland.
• Access to Smart Box’s established network of healthcare professionals and end-users.
• Strengthening Control Bionics’ presence in the European market.

Jeremy Steele, CEO of Control Bionics, commented: “The NeuroNode® has already been paired with hundreds of Smart Box
devices and devices with Smart Box software around the world.”

Read the ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240909/pdf/067np1hzgg2sbv.pdf